Generalized Anxiety Disorder

A 7-week, double blind, placebo-controlled study of an investigational medication for the treatment of generalized anxiety disorder (GAD). GAD is characterized by chronic worrying and constantly high levels of anxiety, both lasting for more than six months. Study visits, mental and physical health evaluations and investigational medication are provided free of charge. Travel compensation is available. There have been more than 10 studies with this compound done to this date. Patients will take medication twice daily. Visits are once a week for the 7 weeks duration of the study.

DuPont Clinical Research
Principal Investigator: 
Caroline M. DuPont, MD
Eligibility Criteria: 

Patients must be between 18 and 70 years of age and meet diagnostic criteria for generalized anxiety disorder. Patients must be in good physical health and free of drug or alcohol addiction problems. Women must agree to use double barrier method birth control. All participants must avoid grapefruit juice or alcohol during the study. Patients must be able to understand procedures and agree to participate in the study by giving written informed consent.

DuPont Clinical Research, (301) 231-9010
Rockville, MD

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910


Contact ADAA

Request Publications



ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.


Privacy Policy 
© ADAA, 2010-2014